Financials in USD. Standardized financial statements.
A compact view of how Alterity Therapeutics Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $5.44M | $4.02M | $3.92M | $5.12M | $4.34M | $0 | $4.95M | $201,174 | $132,396 | $142,657 |
| Revenue Growth? | +35.3% | +2.6% | -23.6% | +18.1% | 0.0% | -100.0% | +2361.1% | +51.9% | -7.2% | 0.0% |
| Cost of Revenue? | $127,523 | $214,304 | $102,263 | $54,214 | $360,026 | $352,922 | $322,097 | $21,799 | $21,328 | $22,810 |
| Gross Profit? | $5.31M | $3.80M | $3.81M | $5.07M | $3.98M | -$352,922 | $4.63M | $179,375 | $111,068 | $119,847 |
| Gross Margin? | +97.7% | +94.7% | +97.4% | +98.9% | +91.7% | 0.0% | +93.5% | +89.2% | +83.9% | +84.0% |
| Operating Expenses? | $19.89M | $23.41M | $18.24M | $20.26M | $19.16M | $13.53M | $17.29M | $11.10M | $6.77M | $8.49M |
| Operating Income? | -$14.57M | -$19.60M | -$14.61M | -$15.50M | -$15.18M | -$13.89M | -$12.66M | -$10.63M | -$6.88M | -$8.59M |
| EBITDA? | -$14.63M | -$19.57M | -$14.60M | -$15.48M | -$15.16M | -$13.90M | -$12.77M | -$8.17M | -$6.86M | -$8.56M |
| Income Before Tax | -$12.08M | -$19.08M | -$13.70M | -$12.78M | -$15.31M | -$13.46M | -$12.34M | -$8.27M | -$7.54M | -$7.73M |
| Income Tax Expense | $68,055 | $46,088 | $104,459 | $70,008 | $0 | $0 | $0 | $270,860 | $660,213 | $0 |
| Net Income? | -$12.15M | -$19.12M | -$13.81M | -$12.85M | -$15.31M | -$13.46M | -$12.34M | -$8.27M | -$7.54M | -$7.73M |
| EPS? | $-0.10 | $-0.26 | $-0.28 | $-0.27 | $-0.45 | $-0.75 | $-1.00 | $-0.78 | $-0.70 | $-0.72 |
| Diluted EPS? | $-0.10 | $-0.26 | $-0.28 | $-0.27 | $-0.45 | $-0.75 | $-1.00 | $-0.78 | $-0.70 | $-0.72 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality